

AB InBev

Price EUR109.05

Conf call feedback and updating forecasts

Fair Value EUR109 (0%)

NEUTRAL

Bloomberg	ABI BB
Reuters	ABI.BR
12-month High / Low (EUR)	123.3 / 91.3
Market Cap (EURm)	175,379
Ev (BG Estimates) (EURm)	250,666
Avg. 6m daily volume (000)	1,720
3y EPS CAGR	6.9%

	1 M	3 M	6 M	31/12/15
Absolute perf.	0.0%	1.6%	-1.0%	-4.7%
Food & Bev.	-0.8%	-0.3%	-6.8%	-5.1%
DJ Stoxx 600	1.4%	2.1%	-12.1%	-9.0%

YEnd Dec. (USDm)	2015	2016e	2017e	2018e
Sales	43,604	43,076	59,609	62,027
% change		-1.2%	38.4%	4.1%
EBITDA	16,921	16,885	24,041	25,884
EBIT	13,768	13,842	20,172	21,899
% change		0.5%	45.7%	8.6%
Net income	8,513	7,712	11,388	12,448
% change		-9.4%	47.7%	9.3%

	2015	2016e	2017e	2018e
Operating margin	31.6	32.1	33.8	35.3
Net margin	19.5	17.9	19.1	20.1
ROE	20.2	17.9	13.7	14.3
ROCE	10.1	10.3	10.5	8.7
Gearing	98.7	101.3	104.7	97.1

(USD)	2015	2016e	2017e	2018e
EPS	5.10	4.62	5.71	6.24
% change	-	-9.4%	23.5%	9.3%
P/E	24.4x	26.9x	21.8x	19.9x
FCF yield (%)	3.7%	3.2%	5.7%	5.1%
Dividends (USD)	2.68	2.43	3.00	3.28
Div yield (%)	2.2%	2.0%	2.4%	2.6%
EV/Sales	6.5x	6.6x	5.5x	5.3x
EV/EBITDA	16.8x	16.9x	13.7x	12.6x
EV/EBIT	20.7x	20.6x	16.4x	14.9x

After poor Q1 numbers we are lowering our 2016 revenue and EBIT by about 2/3% which assumes that the business (especially Brazil and US) picks up in the coming quarters as per guidance from the company. On the call there was also some update on the state of the SABMiller process, but there was no clarification on why suddenly also the Central and Eastern European SABMiller assets are put up for sale. We read it as if the company is getting nervous about South African clearance and desperately want the European regulator Phase1 approval, out of fear that the South African one would continue to seek postponements. (not such a good sign)

On the call, the company was trying to soothe investors' fears on negative developments in Brazil, China and the US, pointing to some temporary headwinds which should subside over the coming quarters. Nevertheless this does not take away that q1 was bad and that impacts our full year earnings outlook. We have lowered our 2016 revenue and operating profit forecasts by 2/3%. We are lowering our 2016 net revenue forecast by 2.3% to USD43.1bn from USD44.1 and our operating profit forecast by 2.9% to USD13.8bn from USD14.3bn before and are now looking for more or less flat figures for the full year 2016. We leave our fair value unchanged at EUR109.

ANALYSIS

- Although q1 volumes in Latam-North were down by 7.3% (-10% in Brazil) and revenue by 1.9%, AB InBev continues to guide to mid to high single digit organic revenue growth for the region, which would assume positive growth in Brazil for the coming quarters. Although no figure has been mentioned, management insists that volume trends in Brazil in April were significantly better than the first quarter and as a result it was not making any change to their guidance for the full year. So what happened in the first quarter is definitely a reflection of the poor macro, but the earlier Carnival (regarded by consumers as the end of the summer) and price increases (ahead of competitors driving temporary loss of market share) exacerbated the volume weakness (and margin contraction).
- A similar story on China. The company believes that its lower revenue per hl growth of 2.1% (well below the 9.4% reported for the full year 2015) is temporary although that it expects industry volumes to continue to be weak. The favourable brand mix development (selling more premium Budweiser) was balanced by unfavourable regional mix because the south and the east, especially Guangdong had very cool weather and very strong economic headwinds; and that is something that affected a region where Budweiser is very strong. That rippled throughout the China numbers. However, Budweiser continued to grow throughout China, with the exception of Guangdong, where it nevertheless gained share on a very weak industry numbers. Overall in China AB InBev's volumes were down just over 1% compared to an industry down 4%, leading to a 45bps market share gain for the quarter (reaching 19%). Premium and super premium beer continue to grow stronger and is now more than 50% of AB InBev's China volumes.
- On the slow down in price/mix in the US from 2.9% in 2015 to 1.2% in Q1, despite the craft brew acquisition, management clarified during the call that there was a phasing on Stella shipments. A year-plus ago it had an issue with Stella being frozen whilst crossing the ocean. And this year, they decided to ship earlier and avoid the harsher part of the winter (December-January). Not only did that impact the price/mix but also that the sales-to-retailers (-0.3%) was well ahead of the sales-to-wholesalers (-1.2%) – which comes in AB InBev's revenue figure. For the full year the difference between the two should disappear and also price/mix should be back up.
- The company also updated on the SABMiller acquisition highlighting the proactive steps it has been taking in addressing any potential regulatory considerations. It believes it has been making good progress in all four of the markets where regulatory clearance is a precondition to making the formal offer to shareholders. It did announce the sale of SABMiller's interest in MillerCoors in the U.S. and in CR Snow in China, as well as the disposal of certain of SABMiller's premium brands and related businesses in Europe, including Peroni and Grolsch. Also, last week, it announced it was divesting SABMiller's Central and Eastern Europe business and brands (Poland, Hungary, Czech Republic, Slovakia, and Romania). During the call, there was some explanation sought on the latter decision especially as there does not seem to be any obvious regulatory concerns in mostly duopoly markets (with Heineken) where profitability is relatively high. But analysts were left puzzled. Maybe, the continuous postponement of the South African regulator (today again



postponement to 12 May), is putting the company in panic mode?

- There were also some interesting comments on further acquisitions. First of all the Dutra (the CFO), highlighted that M&A remains a core competency, and “we'll always be ready to look at opportunities when and if they arise, subject to our strict financial discipline”. Second there is a bonus pool of USD300m for the 65 top managers (excluding the 16 top managers who are on the executive management board), if the company would achieve USD100bn turnover target by 2020 (organic or external growth – and it could be 2020 2021 or 2022). But, although it was not said with so many words, we deduct from Brito’s (CEO) comments during the call that a similar, non-public, target exists for the managers on the executive management board, including himself and the CFO, as most of these bonus plans are there to align with internal targets and that they like “to dream big”. In our forecast the company would make USD67bn revenue in 2020, which is USD33bn short of the target. So which acquisition could fit to reach that target of lifting revenues by another 50% (and that is in the next four years!). There are two companies that could be considered: Coca Cola (USD44bn revenue) or PepsiCo (USD31bn revenue in beverages). Coca Cola’s CEO Kent has warned his management that 3G Capital Partners (controlling shareholders of AB InBev) could try to acquire the company (3G co-investor Warren Buffet already is the largest Coke shareholder). And SABMiller is bottling Coke in numerous markets in Southern Africa and Central America (Honduras and El Salvador). On the other hand AB InBev has long standing relationships with PepsiCo (including a comment buying platform in the US and being their Bottler in Brazil, Argentina, Bolivia, Uruguay, Peru and the Dominican Republic). Furthermore PepsiCo’s revenues of USD63bn are USD31bn beverages and USD32bn snacks which could facilitate a joint offer from AB InBev and Kraft Heinz (also controlled by 3G Capital Partners). Coca Cola’s operating margin is already 20%, the one of PepsiCo is 14%... But maybe first get the SABMiller deal done?

VALUATION

- Our DCF based fair value of USD109 is based on a risk free rate of 1.7%, a risk premium of 7% and a terminal growth rate of 3.7%.
- Valued at 25.7x 2016 earnings include an expectation that the SABMiller deal will be strongly earnings enhancing.

NEXT CATALYSTS

- 29-Jul-2016 Second Quarter and Half Year 2016 Results
- 28-Oct-2016 Third Quarter and Nine Months 2016 Results

[Click here to download](#)



Analyst :
Nikolaas Faes
33(0) 1 56 68 75 72
nfaes@bryangarnier.com

Sector Team :
Loïc Morvan
Antoine Parison
Cédric Rossi
Virginie Roumage

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 72%

NEUTRAL ratings 0%

SELL ratings 28%

Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	No
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London	Paris	New York	Munich	New Delhi
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	Widenmayerstrasse 29	The Imperial Hotel Janpath
15 St. Botolph Street	75008 Paris	New York, NY 10022	80538 Munich	New Delhi 110 001
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Germany	Tel +91 11 4132 6062
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	+49 89 2422 62 11	+91 98 1111 5119
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member		Fax +91 11 2621 9062
Authorised and regulated by the	Financial Conduct Authority (FCA) and the			Geneva
Financial Conduct Authority (FCA)	Autorité de Contrôle prudentiel et de			rue de Grenus 7
	resolution (ACPR)			CP 2113
				Genève 1, CH 1211
				Tel +4122 731 3263
				Fax+4122731 3243
				Regulated by the FINMA

Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available.